[FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure].
A 68-year-old woman was on dialysis for the treatment of chronic renal failure. FOLFOX 4 therapy was performed following CPT-11+UFT+Leucovorin for liver metastasis after resection of cancer of the sigmoid colon. The dose of oxaliplatin was 40 mg/m2, while 5-FU was given as a bolus of 300 mg/m2, and a continuous intravenous infusion of 500 mg/m2. Hemodialysis was performed 1 hour after administration of oxaliplatin on day 1 and was repeated two days later after the completion of drug administration. Vomiting (grade 2),anorexia and leukopenia (both grade 3) were observed after the first treatment. A total of 4 courses were administered thereafter by reducing the dose of oxaliplatin to 32 mg/m2, the intravenous bolus of 5-FU to 240 mg/m2, and continuous infusion of 5-FU to 400 mg/m2. Measurement of drug concentrations showed that free platinum was immediately eliminated by dialysis. It was considered possible to safely perform FOLFOX 4 therapy in patients with chronic renal failure by reducing the doses and by providing dialysis. It is desirable to measure drug concentrations in these patients. Also,more cases should be monitored to investigate the safe dose,the blood drug concentration profile, and the accumulation of chemotherapy agents.
Ohnishi
Tadashi
T
Dept. of Surgery, NTT West Osaka Hospital.
Kanoh
Toshiyuki
T
Shiozaki
Ken
K
Kimura
Yutaka
Y
Iwazawa
Takashi
T
Tono
Takeshi
T
Nakano
Yoshiaki
Y
Yano
Koji
K
Mizuno
Hitoshi
H
Shin
Sunghyo
S
Monden
Takushi
T
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004333:Drug Administration Routes; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D002955:Leucovorin / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000097:blood; D000077150:Oxaliplatin; D010984:Platinum / Q000097:blood; D006435:Renal Dialysis; D012811:Sigmoid Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010984:Platinum; D002955:Leucovorin; D005472:Fluorouracil